Form D · Venture Capital Fund

270 Life Sciences Private Capital Fund II (Cayman) LP

New York, NY · CIK 0002154213

Offering snapshot reported Sep 16, 2026 · SEC filing

Reported sold
Yet to sell
Indefinite offering
Investors reported
0
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 16, 2026InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Pooled investment fund
Exemptions
06b, 3C, 3C.1, 3C.7
Duration over one year
Yes
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0 (estimated)
Form D file number
021-597634
The general partner of the Issuer reserves the right to offer a greater or lesser amount of limited partner interests. Total Offering Amount and Total Remaining to be Sold are aggregated with 270 Life Sciences Private Capital Fund II (US) LP.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
J.P. Morgan Securities LLC79
J.P. Morgan Institutional Investments Inc.102920

Source: Form D, filed Sep 16, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
N/A 270 Life Sciences Private Capital Fund Ii Gp Ltd. Director
Samantha Beattie Executive
Gaurav Gupta Executive
Patrick Mc Goldrick Executive
Stephen Squinto Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:
390 Madison Avenue 27 Th Floor
New York, NY, 10017